Innovative intradermal injection device for lymphoscintigraphy and sentinel lymph node mapping
Breast cancer is the most diagnosed cancer in women, with over 2.3 million cases annually and significant global mortality. Accurate staging, including lymph node involvement, is critical for effective treatment. Sentinel lymph node (SLN) mapping is the standard for assessing nodal metastasis and involves radioisotopes or fluorescent dyes.
Methods for administering mapping agents, radioisotopes or fluorescent dyes, include intradermal (ID), intraparenchymal, and subdermal injections, each with specific characteristics.
ID injection has shown significantly higher frequency of successful localization, reduced time to initial localization through preoperative lymphoscintigraphy, and decreased time for harvesting the first SLN. Therefore, intradermal delivery of radio-istopes or dyes offers a promising option for sentinel lymph node mapping (1).
However, the currently used Mantoux technique for intradermal injection requires a high amount of training and is difficult to standardize. Additionally, It has been shown that about 70% of intradermal injections using the Mantoux technique are incorrectly administered.
VAX-ID offers an innovative intradermal injection device for lymphoscintigraphy and sentinel lymph node mapping. This device offers a solutions the problems encountered with the Mantoux technique.
Some of VAX-ID® ‘s unique propositions include:
- Easy to use
- Accurate and reliable intradermal injection of medicinal products with a predefined penetration depth
- Activation protection and needle-stick injury prevention
- Low in pain
- Dose sparing